drugset / Trial / NCT00238121
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
NaSingle-groupOpen-labelTreatment
Summary
Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well sorafenib works in treating patients with advanced or recurrent uterine cancer.
Timeline
- Start
- 2005-02
- Primary completion
- 2010-07
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | — | Oral |